Heron Therapeutics Inc

Heron Therapeutics, Inc. is a biotechnology company. The Company uses its technology to develop products to address unmet medical needs. Its Biochronomer polymer-based drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals. The Company's product candidate, SUSTOL (granisetron injection, extended release), is being developed for the prevention…More of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). Sustol is in Phase III Clinical trials. The Company's product development program also focuses on identifying new delivery methods and formulations utilizing known compounds that may expand or extend the therapeutic effort, or eliminate the drawbacks of current therapies. The Company's other product candidates include HTX-019 for CINV, which is in Preclinical state; HTX-011 for Post-operative pain management, which is in Phase I trials, and HTX-003 for chronic pain management, which is in Preclinical state.